Cinda bio authorizes the commercial rights and interests of bevacizumab in the United States and Canada to coherus Biosciences

On January 14, the board of directors of Cinda biological Co., Ltd happily announced that the company has reached a cooperation agreement with coherus Biosciences, Inc to authorize the group's commercial rights and interests of avidin ® (bevacizumab) bio similar drugs (ibi-305) in the United States and Canada to coherus Biosciences Co., Ltd Coherus plans to submit a biological product license application (BLA) to the U.S Food and Drug Administration (FDA) from the end of 2020 to the beginning of 2021 (the specific time depends on the progress of FDA approval), and start commercial sales after approval Ibi305 has successfully completed a large clinical phase 3 safety and effectiveness study in China, and its new drug listing application has been accepted by China Drug Administration (nmpa) in January 2019, and then obtained the priority review qualification Under the terms of the agreement, coherus will also have a non exclusive priority to develop and commercialize Cinda bio's rituximab bioequivalent drug (Cinda bio R & D Code: ibi301) in the United States and Canada The new drug listing application of ibi301 has been accepted by nmpa in June 2019 and has obtained the priority review qualification According to the terms of the agreement, coherus will pay Cinda bio a down payment and milestone payment of US $45 million for the commercialized interest of ibi305 In addition, based on the future sales of ibi305, coherus will also pay Cinda's double-digit percentage of sales When ibi301 is preferred by coherus, the payment terms it enjoys will be consistent with ibi305 Adorable adorable